Conference
Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Authors
Landsburg DJ; Frigault M; Heim M; Foley SR; Hill BT; Ho CM; Jacobson CA; Jaglowski S; Locke FL; Ram R
Volume
140
Pagination
pp. 1584-1587
Publisher
American Society of Hematology
Publication Date
November 15, 2022
DOI
10.1182/blood-2022-158822
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971